West Pharmaceutical Services (WST) Operating Expenses (2009 - 2026)

West Pharmaceutical Services has disclosed Operating Expenses across 18 years of filings, most recently posting $115.3 million for Q1 2026.

• Operating Expenses for Q1 2026 came in at $115.3 million, up 10.55% year-over-year; the trailing twelve-month figure through Mar 2026 was $478.9 million (up 17.49% YoY), and the FY2025 annual result was $467.9 million, up 14.79% from the prior year.
• Operating Expenses came in at $115.3 million for Q1 2026 at West Pharmaceutical Services, down from $128.8 million in the prior quarter.
• In the past five years, Operating Expenses ranged from a high of $128.8 million in Q4 2025 to a low of $79.9 million in Q3 2022.
• The 5-year median for Operating Expenses is $104.3 million (2024), against an average of $105.2 million.
• Across the five-year window, Operating Expenses slipped 23.9% in 2022 and surged 31.91% in 2023, its largest moves.
• West Pharmaceutical Services' Operating Expenses stood at $101.6 million in 2022, then gained by 6.69% to $108.4 million in 2023, then slipped by 4.24% to $103.8 million in 2024, then advanced by 24.08% to $128.8 million in 2025, then slipped by 10.48% to $115.3 million in 2026.
• The last three Operating Expenses figures came in at $115.3 million (Q1 2026), $128.8 million (Q4 2025), and $119.8 million (Q3 2025), per Business Quant data.